Institution
Université catholique de Louvain
Education•Louvain-la-Neuve, Belgium•
About: Université catholique de Louvain is a education organization based out in Louvain-la-Neuve, Belgium. It is known for research contribution in the topics: Population & Catalysis. The organization has 25319 authors who have published 57360 publications receiving 2172080 citations. The organization is also known as: University of Louvain & UCLouvain.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Recent progress in the understanding of the glucocorticoid-induced muscle atrophy should allow to define new therapies aiming to minimize this myopathy, which is characterized by fast-twitch or type II muscle fiber atrophy illustrated by decreased fiber cross-sectional area and reduced myofibrillar protein content.
Abstract: Glucocorticoid-induced muscle atrophy is characterized by fast-twitch or type II muscle fiber atrophy illustrated by decreased fiber cross-sectional area and reduced myofibrillar protein content. Muscle proteolysis, in particular through the ubiquitin- proteasome system (UPS), is considered to play a major role in the catabolic action of glucocorticoids. The stimulation by glucocorticoids of the UPS is mediated through the increased expression of several atrogenes ('genes involved in atrophy'), such as atrogin-1 and MuRF-1, two ubiquitin ligases involved in the targeting of protein to be degraded by the proteasome machinery. Glucocorticoids also exert an anti-anabolic action by blunting muscle protein synthesis. These changes in protein turnover may result from changes in the production of two growth factors which control muscle mass, namely IGF-I and myostatin respectively anabolic and catabolic toward the skeletal muscle. The decreased production of IGF-I as well as the increased production of myostatin have been both demonstrated to contribute to the muscle atrophy caused by glucocorticoids. At the molecular level, IGF-I antagonizes the catabolic action of glucocorticoids by inhibiting, through the PI3-kinase/Akt pathway, the activity of the transcription factor FOXO, a major switch for the stimulation of several atrogenes. These recent progress in the understanding of the glucocorticoid-induced muscle atrophy should allow to define new therapies aiming to minimize this myopathy. Promising new therapeutic approaches for treating glucocorticoid-induced muscle atrophy are also presented in this review.
410 citations
••
TL;DR: The present paper offers an update on the genotoxic status of OTA, which is still controversial because contradictory results were obtained in various microbial and mammalian tests, notably regarding the formation of DNA adducts.
410 citations
•
30 Jul 2014
409 citations
••
The Breast Cancer Research Foundation1, Institut Gustave Roussy2, Texas Oncology3, Harvard University4, Ege University5, BC Cancer Agency6, Guy's and St Thomas' NHS Foundation Trust7, Pontifícia Universidade Católica do Rio Grande do Sul8, Medical University of Vienna9, Université catholique de Louvain10, Magna Græcia University11, Complutense University of Madrid12
TL;DR: The primary outcome was invasive disease-free survival, as defined in the original protocol, at 2 years after randomisation, in patients with early-stage HER2-positive breast cancer.
Abstract: Summary Background Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer. Methods We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 495 centres in Europe, Asia, Australia, New Zealand, and North and South America. Eligible women (aged ≥18 years, or ≥20 years in Japan) had stage 1–3 HER2-positive breast cancer and had completed neoadjuvant and adjuvant trastuzumab therapy up to 2 years before randomisation. Inclusion criteria were amended on Feb 25, 2010, to include patients with stage 2–3 HER2-positive breast cancer who had completed trastuzumab therapy up to 1 year previously. Patients were randomly assigned (1:1) to receive oral neratinib 240 mg per day or matching placebo. The randomisation sequence was generated with permuted blocks stratified by hormone receptor status (hormone receptor-positive [oestrogen or progesterone receptor-positive or both] vs hormone receptor-negative [oestrogen and progesterone receptor-negative]), nodal status (0, 1–3, or ≥4), and trastuzumab adjuvant regimen (sequentially vs concurrently with chemotherapy), then implemented centrally via an interactive voice and web-response system. Patients, investigators, and trial sponsors were masked to treatment allocation. The primary outcome was invasive disease-free survival, as defined in the original protocol, at 2 years after randomisation. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00878709. Findings Between July 9, 2009, and Oct 24, 2011, we randomly assigned 2840 women to receive neratinib (n=1420) or placebo (n=1420). Median follow-up time was 24 months (IQR 20–25) in the neratinib group and 24 months (22–25) in the placebo group. At 2 year follow-up, 70 invasive disease-free survival events had occurred in patients in the neratinib group versus 109 events in those in the placebo group (stratified hazard ratio 0·67, 95% CI 0·50–0·91; p=0·0091). The 2-year invasive disease-free survival rate was 93·9% (95% CI 92·4–95·2) in the neratinib group and 91·6% (90·0–93·0) in the placebo group. The most common grade 3–4 adverse events in patients in the neratinib group were diarrhoea (grade 3, n=561 [40%] and grade 4, n=1 [ vs grade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%] vs n=5 [ vs n=2 [ Interpretation Neratinib for 12 months significantly improved 2-year invasive disease-free survival when given after chemotherapy and trastuzumab-based adjuvant therapy to women with HER2-positive breast cancer. Longer follow-up is needed to ensure that the improvement in breast cancer outcome is maintained. Funding Wyeth, Pfizer, Puma Biotechnology.
409 citations
••
01 Oct 1996TL;DR: An approach to goal refinement and operationalization which is aimed at providing constructive formal support while hiding the underlying mathematics is presented, and the general principle is to reuse generic refinement patterns from a library structured according to strengthening/weakening relationships among patterns.
Abstract: Requirements engineering is concerned with the identification of high-level goals to be achieved by the system envisioned, the refinement of such goals, the operationalization of goals into services and constraints, and the assignment of responsibilities for the resulting requirements to agents such as humans, devices and programs. Goal refinement and operationalization is a complex process which is not well supported by current requirements engineering technology. Ideally some form of formal support should be provided, but formal methods are difficult and costly to apply at this stage.This paper presents an approach to goal refinement and operationalization which is aimed at providing constructive formal support while hiding the underlying mathematics. The principle is to reuse generic refinement patterns from a library structured according to strengthening/weakening relationships among patterns. The patterns are once for all proved correct and complete. They can be used for guiding the refinement process or for pointing out missing elements in a refinement. The cost inherent to the use of a formal method is thus reduced significantly. Tactics are proposed to the requirements engineer for grounding pattern selection on semantic criteria.The approach is discussed in the context of the multi-paradigm language used in the KAOS method; this language has an external semantic net layer for capturing goals, constraints, agents, objects and actions together with their links, and an inner formal assertion layer that includes a real-time temporal logic for the specification of goals and constraints. Some frequent refinement patterns are high-lighted and illustrated through a variety of examples.The general principle is somewhat similar in spirit to the increasingly popular idea of design patterns, although it is grounded on a formal framework here.
409 citations
Authors
Showing all 25540 results
Name | H-index | Papers | Citations |
---|---|---|---|
Robert Langer | 281 | 2324 | 326306 |
Pulickel M. Ajayan | 176 | 1223 | 136241 |
Klaus Müllen | 164 | 2125 | 140748 |
Giacomo Bruno | 158 | 1687 | 124368 |
Willem M. de Vos | 148 | 670 | 88146 |
David Goldstein | 141 | 1301 | 101955 |
Krzysztof Piotrzkowski | 141 | 1269 | 99607 |
Andrea Giammanco | 135 | 1362 | 98093 |
Christophe Delaere | 135 | 1320 | 96742 |
Vincent Lemaitre | 134 | 1310 | 99190 |
Michael Tytgat | 134 | 1449 | 94133 |
Jian Li | 133 | 2863 | 87131 |
Jost B. Jonas | 132 | 1158 | 166510 |
George Stephans | 132 | 1337 | 86865 |
Peter Hall | 132 | 1640 | 85019 |